top of page
Picture1.jpg

SirTLab Corporation

SEVERE LIVER  DISEASE&LONGEVITY

About

ABOUT 

SirTLab is the leader in Restoring SIRT6 Expression for Severe Liver Diseases and Diseases of Aging

•Sirtuin 6 (SIRT6) is a Key Regulator for Health in All Cells.

•Levels of SIRT6 are reduced in liver diseases: NASH1, other cirrhosis, metabolic syndrome, acetaminophen toxicity.

•SIRTLab patented SIRT6-mRNA-LNP2 for liver specific expression of SIRT6 based on >18 years of research.

•First in Human expected in 2H 2023

•Potential for truly disease modifying therapy for a variety of severe liver disorders

1NASH   non-alcoholic steatohepatitis

2LNP   lipid nanoparticle

SirTLab Corporation ©2022 | Confidential and Proprietary

תמונה 2_edited_edited.jpg
Features

Livers from Mice with NAFL1 (Stage 2 / 3 – Fatty, Early Fibrotic)

CONTROL Treatment

SIRT6 mRNA-LNP IV BIW x 3 wks

Fatty, Fibrotic Liver

Restored Normal Liver

SIRT6 mRNA for:

·Non-Alcoholic Fatty Liver (NAFL):

·Focus on NASH Stages 3 & 4

·Aging and Frailty

·Liver cirrhosis (viral, alcoholic)

·Type II diabetes

·Hyperlipidemia

·Obesity

·Neurodegenerative Diseases

·Liver cancer (HCC)

Data on File, SIRTLab Corporation (2 days after last dose)

1NAFL   non-alcoholic fatty liver

2BIW   twice per week

SirTLab Corporation ©2022 | Confidential and Proprietary

Projects

PROJECTS

Contact
bottom of page